Lilly Amasses $1.5B Stockpile for Oral Obesity Drug as Logistics and Amylin Sectors Surge

Eli Lilly has accumulated a $1.5 billion stockpile of its experimental oral obesity pill orforglipron ahead of an expected FDA decision in April, while new research shows combining GLP-1 receptor agonists with progestins could reduce endometrial cancer risk by 66%. The developments come as logistics companies invest heavily in temperature-controlled infrastructure to support booming demand for weight-loss drugs, and the amylin-based obesity therapy space sees a surge in deal-making and clinical progress.

Lilly's massive inventory—nearly triple what it was a year ago—is a direct move to avoid the supply shortages that have crippled the GLP-1 market. As the first small-molecule oral GLP-1 to finish Phase III, the company is betting that orforglipron’s easy manufacturing and room-temperature stability will define the next decade of metabolic care. Currently, most injectable GLP-1 medications, including Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound, require refrigerated storage for shipment. The FDA has warned that improper storage can render these drugs ineffective.

In a separate study published in JAMA Network Open, researchers found that combining GLP-1 receptor agonists with progestins led to an approximately 66% reduction in endometrial cancer risk among women with nonmalignant uterine conditions. The therapy also appeared to reduce the need for hysterectomies, suggesting potential benefits beyond metabolic health.

Logistics providers are racing to meet the demands of this expanding market. UPS recently announced a $48 million investment in temperature-controlled facilities as part of its expanding healthcare logistics portfolio. The company reported its first $3 billion healthcare revenue quarter in the first quarter of 2026, with its global healthcare portfolio gaining market share every year since 2021. According to UPS, there is 'rapid growth' in biologics, cell and gene therapies, though the margin for error is small—even a brief temperature deviation can ruin these medicines.

FedEx has launched a life sciences organization to support pharmaceutical movements, with healthcare transportation revenue reaching nearly $10 billion in fiscal year 2026. The company is leveraging its existing infrastructure, including its airline and machine learning-based tracking system, to handle the increasing complexity of GLP-1 deliveries from injectables to oral forms. C.H. Robinson also surpassed $1 billion in healthcare logistics revenue over the past year, largely fueled by GLP-1 drug demand.

Meanwhile, the amylin drug class is emerging as a major frontier in obesity treatment. A new report from PatentVest highlights nearly 40 amylin receptor agonist programs in development globally, with more than $19 billion in deal value committed over the past 18 months by companies including Novo Nordisk, Eli Lilly, Roche, Pfizer, and AbbVie. Key findings from the report include:

• Nearly 40 amylin receptor agonist programs in development worldwide
• The first GLP-1/amylin combination therapy approaching FDA decision
• Clinical data demonstrating up to 20%+ weight loss with amylin-based therapies
• The emergence of oral small-molecule amylin programs as a potential market-expanding force
• The critical role of patent strategy in determining long-term competitive advantage

'The winners won’t just be those with the best molecule, but those with the most sophisticated intellectual property architecture,' said the Chief IP Officer of PatentVest. The next 18 months are expected to bring major clinical readouts and regulatory decisions that will reshape the competitive landscape.

A July Gallup poll found that 11% of Americans take GLP-1 medications for weight loss purposes in 2026, up from just 3% in 2024, underscoring the rapid adoption driving these industry-wide investments.